Our blog

Neurology and Neuropsychology team specializes in the evaluation of biomarkers and the early diagnosis of…

Compartir:

The Pasqual Maragall Foundation develops a method based on magnetic resonance imaging It allows to…

Compartir:

The General University Hospital of Catalonia analyzes in two proteins and in a gum bacterium…

Compartir:

Our team participated in a phase II clinical trial, with an antiamyloid monoclonal antibody in…

Compartir:

We have initiated a clinical trial to assess the efficacy and safety of a drug…

Compartir:

We have been selected to evaluate an innovative therapy in this terrible disease. We will…

Compartir:

We started a phase II / III trial with an inhibitor of TAU protein aggregation…

Compartir:

New formulation of combined action Levodopa We have started the evaluation of a new preparation…

Compartir:

We have started a clinical trial with a new antidiskinetic therapy (combination of two drugs…

Compartir:

The UDIC will shortly begin a clinical trial to evaluate the subcutaneous administration of levodopa,…

Compartir:

Our Unit participated in a Phase II clinical trial, with a monoclonal anti-amyloid in Alzheimer’s,…

Compartir:

Our Unit has surpassed two centers from the United States in the randomization of patients included in a…

Compartir:
Page 2 of 3 1 2 3

1 Nuevo anticuerpo monoclonal antialfasinucleina Ensayo Clínico de fase II para evaluar eficacia y seguridad
en enfermedad de Parkinson inicial en pacientes que no reciben medicamentos antiparkinsonianos en el momento actual.
2 Nuevo fármaco antipsicótico en cualquier tipo de demencia. Ensayo de Fase III que evalúa un antipsicótico
en cualquier tipo de delirio o alucinaciones. Sin acción antidopaminérgica, especialmente indicado en Parkinson
o en situaciones de mala respuesta a los neurolepticos
Compartir: